Business context and reporting period
Filing identity mismatch: The supplied filing is Transgenomic, Inc.’s Form 10-Q for the quarter ended September 30, 2014, not a filing identified as Precipio, Inc. The financial information below pertains to Transgenomic. The company operated Laboratory Services and Genetic Assays and Platforms businesses.
Key financial metrics
Amounts are in millions of dollars except per-share data and percentages. Interim financial statements are unaudited.
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $6.37 | $6.65 | $19.39 | $21.33 |
| Gross profit / margin | $2.22 / 35% | $2.45 / 37% | $7.10 / 37% | $8.68 / 41% |
| Operating loss | $(4.01) | $(5.41) | $(11.50) | $(12.15) |
| Net loss | $(0.08) | $(5.55) | $(8.15) | $(12.01) |
| Net loss available to common shareholders | $(0.38) | $(5.73) | $(8.99) | $(12.55) |
Q3 loss per common share was $(0.05), versus $(0.78) a year earlier; nine-month loss per share was $(1.22), versus $(1.73). Q3 2014 results included a $4.1 million gain on the Surveyor product-line sale.
For the first nine months, operating cash use was $11.21 million, investing cash provided was $3.47 million, and financing cash provided was $6.99 million. Cash declined $0.75 million to $0.88 million. At September 30, working capital was $3.88 million; total debt was $6.99 million, including $1.38 million classified as current. Total liabilities were $20.62 million and stockholders’ equity was $10.23 million.
Material changes versus prior periods
- Q3 revenue declined 4% year over year; nine-month revenue declined 9%. Nine-month Laboratory Services sales fell 8%, and Genetic Assays and Platforms sales fell 11%.
- Gross margin contracted by 2 percentage points in Q3 and 4 points for the nine-month period. Management cited lower contract laboratory and instrument sales; the Genetic Assays and Platforms Q3 margin fell to 19% from 27%.
- Operating losses improved, but lower SG&A—primarily lower bad-debt provisions—contributed to the improvement. The Q3 net-loss comparison was substantially affected by the Surveyor sale gain.
- Accounts receivable rose to $7.51 million from $5.31 million at year-end. The company recorded $2.65 million of doubtful-account provision and wrote off about $1.7 million of prior-period receivables during the first nine months.
- Cash from operations worsened to $11.21 million used from $6.33 million used in the prior-year period, including a $4.86 million increase in receivables.
Outlook, risks, contingencies and unusual items
- On July 1, 2014, Transgenomic sold its Surveyor Kits product line and related technology to IDT for $3.65 million upfront plus $0.60 million in installments; a contingent earn-out may also be payable. Transgenomic retained an exclusive, royalty-free clinical-use license. The company recorded a $4.1 million gain. The first $0.15 million installment was received October 1.
- After quarter-end, the company raised approximately $2.375 million gross in an equity-and-warrant private placement. It also amended its lender agreement, reducing the revolving-line commitment from $4.0 million to $3.0 million and lowering minimum liquidity and revenue covenants. The term-loan payment deferral ran through March 31, 2015, with payments scheduled to resume April 1, 2015.
- Management said cash, available liquidity and the October financing were expected to fund operations for at least 12 months; this is management’s estimate, not a guarantee. Operating losses and cash use, payer reimbursement reductions, collections, sales execution, and access to capital remain material risks.
- Management reported compliance with debt covenants as of September 30, as amended. The debt is secured by company assets and includes a lender subjective-acceleration provision. Certain claims arise in the ordinary course; management did not expect them to have a material adverse effect.
- Management cited an October research agreement with the University of Melbourne and a first commercial MX-ICP agreement with a biopharmaceutical company as early commercialization developments. No quantified revenue outlook or formal financial guidance was provided.
Important facts for investors to verify
- Confirm the issuer: this source is Transgenomic, Inc., despite the request metadata naming Precipio, Inc.
- Review subsequent cash receipts, liquidity and cash burn against management’s 12-month funding expectation.
- Track receivable aging, collections, bad-debt provisions and payer reimbursement levels.
- Assess whether the Surveyor sale proceeds and retained clinical license support the company’s stated strategy, and whether any earn-out is achieved.
- Monitor MX-ICP validation and commercial adoption, revenue trends by segment, and debt covenants and repayment requirements.